Investors with a lot of money to spend have taken a bearish stance on DexCom DXCM.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 11 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $139,269, and 8 are calls, for a total amount of $460,585.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $95.0 for DexCom over the recent three months.
Insights into Volume & Open Interest
In today's trading context, the average open interest for options of DexCom stands at 2165.5, with a total volume reaching 2,631.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $55.0 to $95.0, throughout the last 30 days.
DexCom Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | CALL | SWEEP | BEARISH | 06/20/25 | $14.7 | $14.4 | $14.4 | $75.00 | $109.4K | 159 | 76 |
| DXCM | CALL | SWEEP | NEUTRAL | 01/17/25 | $3.6 | $3.4 | $3.6 | $80.00 | $82.1K | 10.4K | 281 |
| DXCM | CALL | TRADE | BEARISH | 01/17/25 | $2.9 | $2.75 | $2.8 | $82.00 | $77.2K | 99 | 576 |
| DXCM | CALL | SWEEP | BULLISH | 01/17/25 | $3.3 | $3.1 | $3.3 | $82.00 | $60.0K | 99 | 826 |
| DXCM | PUT | SWEEP | BEARISH | 01/17/25 | $2.0 | $1.95 | $1.95 | $77.00 | $51.8K | 19 | 513 |
About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.
DexCom's Current Market Status
- Trading volume stands at 1,506,236, with DXCM's price down by -0.53%, positioned at $80.64.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 31 days.
What The Experts Say On DexCom
3 market experts have recently issued ratings for this stock, with a consensus target price of $94.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for DexCom, targeting a price of $99. * Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on DexCom with a target price of $91. * Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for DexCom, targeting a price of $94.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
